FUND CLOSING

TVM LSI II Final Closing Announced

TVM Capital Life Science, one of the leading life sciences investment firms in North America and Europe, today announced the final closing of its latest fund, TVM Life Science Innovation II (TVM LSI II).

Committed capital totals US$478 million which was raised from high profile international investors, including Eli Lilly and Company, other strategic investors, pension funds, endowments, foundations, fund-of-funds, wealth managers and large US banks as well as multi and single family offices from the Americas, Europe and South Korea.

The geographical focus for the Fund’s investment activity is on North-America and Europe.

TVM LSI II was substantially oversubscribed. The Fund already sold its first investment in February 2020.

TVM LSI II will maintain TVM’s focus on investing in assets that provide a visible and attractive exit strategy from the outset with the goal of maximizing returns and providing early and significant liquidity for its investors. About 50-60% of the Fund‘s capital is intended to be invested in “Project Focused Companies“ (“PFCs“) which are majority-owned by the Fund and set up for the development of early-stage drug candidates in a capital and time efficient manner. The remaining capital will be invested in late clinical stage biopharmaceutical companies as well as commercial stage medical device and diagnostic companies.

The proven focus of TVM LSI II continues on building a portfolio of differentiated first-in-class and best-in-class assets that are diversified by indication and stage of development.

MCAM Group and OCP acted as placement agents for the fund.